Turning up the heat on surgical cold
Sign Up to like & getrecommendations! Published in 2017 at "Temperature"
DOI: 10.1080/23328940.2017.1319453
Abstract: Wouldn’t it be great to be able to develop a completely new drug for less than $60 million in 6 years or less? And to solve a problem associated with significant morbidity (intraoperative hypothermia) during… read more here.
Keywords: hypothermia; approval; trpv1 antagonists; drug ... See more keywords
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.234
Abstract: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ demonstrated rapid and clinically meaningful improvements in disease activity across the full spectrum of axial spondyloarthritis (axSpA; active non-radiographic… read more here.
Keywords: ucb pharma; grants research; pharma; axspa ... See more keywords
P194 Bimekizumab is associated with improvement in quality of life in patients across the full spectrum of axial spondyloarthritis at week 16: results from two phase 3 studies
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.235
Abstract: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A and has demonstrated rapid and clinically meaningful improvements in disease activity (ASAS40, primary outcome measure) in patients across the full… read more here.
Keywords: ucb pharma; improvement; pharma; axspa ... See more keywords
SAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1081
Abstract: Background Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by inhibiting RANKL, a key mediator of osteoclast formation, function, and survival. Objectives To evaluate the effect of denosumab 60 mg… read more here.
Keywords: mitsubishi tanabe; takeda; denosumab; daiichi sankyo ... See more keywords
FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.2467
Abstract: Background Women with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the safety of the use of biologics during breastfeeding.1 Limited and non-validated data exist on the potential transfer of anti-TNFs… read more here.
Keywords: czp; ucb pharma; breast milk; pharma ... See more keywords
THU0339 PULMONARY INVOLVEMENT AND OUTCOME IN SYSTEMIC SCLEROSIS (SSC) – ILD-PH AS AN IMPORTANT SUBSET
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1775
Abstract: Background Pulmonary involvement is the leading cause of death in SSc and can manifest as interstitial lung disease (ILD), pulmonary hypertension (PAH) or a combination (ILD-PH). Aim of this analysis was to determine prevalence, clinical… read more here.
Keywords: speakers bureau; roche; none declared; gmbh ... See more keywords
AB0494 CHARACTERISTICS OF THE PATIENTS WITH POLYARTERITIS NODOSA IN JAPAN
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1289
Abstract: Since the number of polyarteritis nodosa (PAN) patients is small not only in Japan but also in the world, the characteristics of PAN have not been fully clarified and appropriate treatment has not been established.This… read more here.
Keywords: ltd; japan; none declared; pharma ... See more keywords
THU0114 CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2069
Abstract: Background: The presence of rheumatoid factor (RF) in patients (pts) with rheumatoid arthritis (RA) is associated with higher disease activity,1 and is regarded as a risk factor for more aggressive RA.1 Most studies on anti-tumour… read more here.
Keywords: ltd; efficacy; factor; pharma ... See more keywords
THU0086 FACTORS ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: 3-YEAR OBSERVATION USING THE IORRA COHORT.
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.3115
Abstract: Background: Patients with elderly-onset rheumatoid arthritis (EORA) are on the rise in the aging or super-aging society, especially in Japan. Patients with EORA have more comorbidities than those with younger-onset RA, a higher risk of… read more here.
Keywords: ltd; none declared; pharmaceutical ltd; rheumatology ... See more keywords
SAT0315 INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5503
Abstract: Background: Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the formation prostaglandin (PG) E2 from cyclooxygenase derived PGH2(1, 2). Inhibition of mPGES-1 leads to reduction of pro-inflammatory PGE2, while in vessels there is a concomitant increase of… read more here.
Keywords: shareholder gesynta; gesynta pharma; pgi2; pharma ... See more keywords
OP0182 PROTEOGLYCAN LOSS IN ARTICULAR CARTILAGE IS ASSOCIATED WITH JOINT INFLAMMATION SEVERITY IN PSORIATIC ARTHRITIS – A COMPOSITIONAL MAGNETIC RESONANCE IMAGING STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5557
Abstract: Even though cartilage loss is a known feature of psoriatic arthritis (PsA), little is known about its role in the pathogenesis of PsA. Using delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) as a non-invasive… read more here.
Keywords: none declared; pharma; deutschland gmbh; gmbh ... See more keywords